The Experts below are selected from a list of 459 Experts worldwide ranked by ideXlab platform

Hitoshi Saito - One of the best experts on this subject based on the ideXlab platform.

  • Sequential Treatment with Eldecalcitol After PTH Improves Bone Mechanical Properties of Lumbar Spine and Femur in Aged Ovariectomized Rats
    Calcified Tissue International, 2019
    Co-Authors: Sadaoki Sakai, Hitoshi Saito, Satoshi Takeda, Tomoka Hasegawa, Hiromi Hongo, Tomomaya Yamamoto, Koichi Endo, Kenji Yogo, Norio Amizuka
    Abstract:

    Parathyroid hormone (PTH) analogs have a powerful anabolic effect on bone and are used in the treatment of patients with severe osteoporosis. However, there are limitations to how long they can be safely administered. Withdrawal of PTH results in the cancelation of its effects, necessitating subsequent treatment to maintain the bone quantity and quality. This study assessed the effects of Eldecalcitol (ELD), an active vitamin D3 derivative, after PTH in estrogen-deficient osteoporotic rats. Six-month-old female rats were ovariectomized, and PTH administration was started 7 weeks later. After 4 weeks of PTH treatment, the animals were divided into three groups and either continued to receive PTH (PTH–PTH), or were switched to ELD (PTH–ELD) or vehicle (PTH–Veh) for an additional 4 weeks. In the femur, increased BMD by 4 weeks treatment of PTH was significantly reduced in PTH–Veh but not in PTH–PTH and PTH–ELD. The same tendency was observed in the lumbar vertebrae. MicroCT imaging and histomorphometry analysis revealed that the favorable bone structure changes by PTH administration were also maintained in the femurs and tibias of the PTH–PTH and PTH–ELD groups. Increased bone strength by 4-week treatment of PTH in lumber also maintained in PTH–ELD. Furthermore, minimodeling was observed in the PTH–ELD group. These results demonstrate that treatment with ELD sequentially following PTH prevented the bone quantity and strength reduction that accompanies PTH withdrawal in estrogen-deficient rats.

  • Eldecalcitol causes fgf23 resistance for pi reabsorption and improves rachitic bone phenotypes in the male hyp mouse
    Endocrinology, 2018
    Co-Authors: Ichiro Kaneko, Tomoka Hasegawa, Norio Amizuka, Hiroko Segawa, Kayo Ikuta, Ai Hanazaki, Toru Fujii, Sawako Tatsumi, Shinsuke Kido, Hitoshi Saito
    Abstract:

    : X-linked hypophosphatemia (XLH), the most common form of inheritable rickets, is caused by inactivation of phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) and leads to fibroblast growth factor (FGF) 23-dependent renal inorganic phosphate (Pi) wasting. In the present study, we investigated whether maintaining Pi homeostasis with a potent vitamin D3 analog, Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropyloxy) vitamin D3; ED71], could improve hypophosphatemic rickets in a murine model of XLH, the Hyp mouse. Vehicle, ED71, or 1,25-dihydroxyvitamin D was subcutaneously injected five times weekly in wild-type (WT) and Hyp mice for 4 weeks, from 4 to 8 weeks of age. Injection of ED71 into WT mice suppressed the synthesis of renal 1,25-dihydroxyvitamin D and promoted phosphaturic activity. In contrast, administration of ED71 to Hyp mice completely restored renal Pi transport and NaPi-2a protein levels, although the plasma-intact FGF23 levels were further increased. In addition, ED71 markedly increased the levels of the scaffold proteins, renal sodium-hydrogen exchanger regulatory factor 1, and ezrin in the Hyp mouse kidney. Treatment with ED71 increased the body weight and improved hypophosphatemia, the bone volume/total volume, bone mineral content, and growth plate structure in Hyp mice. Thus, ED71 causes FGF23 resistance for phosphate reabsorption and improves rachitic bone phenotypes in Hyp mice. In conclusion, ED71 has opposite effects on phosphate homeostasis in WT and Hyp mice. Analysis of Hyp mice treated with ED71 could result in an additional model for elucidating PHEX abnormalities.

  • The safety and effectiveness profile of Eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report
    Journal of Bone and Mineral Metabolism, 2017
    Co-Authors: Hitoshi Saito, Hiroyuki Kakihata, Yosuke Nishida, Sawako Yatomi, Shigeru Nihojima, Yumiko Kobayashi, Hidehiro Tabata, Makoto Nomura
    Abstract:

    This large-scale post-marketing surveillance study was conducted to assess the safety and effectiveness of Eldecalcitol treatment in patients with osteoporosis in a Japanese clinical setting. A total of 3567 patients with osteoporosis were enrolled and received Eldecalcitol 0.75 μg/day for 12 months. For this interim report, 3285 patients were eligible for analysis. Mean age was 74.9 ± 8.7 years; 86.8 % (2854/3285) were women. There were 142 reported adverse drug reactions (ADRs) in 129 patients (3.92 % of the total 3285 patients): the most common were hypercalcemia and increased blood calcium (0.88 %), renal impairment (0.27 %), abdominal discomfort (0.24 %), constipation (0.24 %), and pruritus (0.24 %). The incidence of ADRs was 5.10 % in men and 3.74 % in women. Although 10 serious ADRs were reported in 9 patients (0.27 %), no clinically significant safety issues were identified. Incidence of hypercalcemia or increased blood calcium was 8.47 % in patients with renal impairment and only 0.74 % in patients without renal impairment. At last observation, the incidence of new vertebral and nonvertebral fractures was 2.44 % and 1.70 %, respectively. There was a significant increase in bone mineral density at the lumbar spine and distal radius. The bone turnover markers BAP, serum NTX, urinary NTX, and TRACP-5b were suppressed by Eldecalcitol treatment in both sexes. In conclusion, consistent with the findings of the phase III pivotal clinical trial, Eldecalcitol was shown to have a favorable safety profile and effectiveness in Japanese patients with osteoporosis. However, periodic measurements of serum calcium were required to prevent occurrence of hypercalcemia during Eldecalcitol treatment, especially in patients with renal impairment.

  • Eldecalcitol reduces osteoporotic fractures by unique mechanisms
    The Journal of Steroid Biochemistry and Molecular Biology, 2015
    Co-Authors: Satoshi Kondo, Toshiyuki Takano, Hitoshi Saito, Toshio Matsumoto
    Abstract:

    Eldecalcitol shows higher binding affinity for vitamin D-binding protein (DBP), tighter binding to vitamin D receptor (VDR), and resistance to metabolic degradation via 24-hydroxylation. In silico analysis of the mode of binding demonstrated that the 3-hydroxypropyloxy (3-HP) group of Eldecalcitol offers additional hydrogen bond and CH–π interaction for the binding to DBP and VDR. However, the 3-HP group interferes with the binding of Eldecalcitol to CYP24A1, causing poor metabolic clearance of Eldecalcitol by this enzyme. These characteristics may contribute to the stronger effect of Eldecalcitol than calcitriol. The present post-hoc analysis also demonstrate that the incidence of hypercalcemia and hypercalciuria is slightly higher in Eldecalcitol than in alfacalcidol group especially in patients with CKD stage 3B, that both serum and urinary calcium return to the baseline levels shortly after cessation of the treatment in both treatment groups, that the incidence of urolithiasis is higher in patients with higher eGFR and is similar between alfacalcidol and Eldecalcitol groups, and that eGFR is transiently reduced by both alfacalcidol and Eldecalcitol treatment especially among patients with higher eGFR but recovers after the end of both treatment. Eldecalcitol can be used for the treatment of osteoporosis without Ca supplementation to reduce the incidence of hypercalcemia and hypercalciuria, and enough hydration is recommended in order to avoid hypercalcemia, urolithiasis and deterioration of renal function.

  • efficacy of combined treatment with alendronate aln and Eldecalcitol a new active vitamin d analog compared to that of concomitant aln vitamin d plus calcium treatment in japanese patients with primary osteoporosis
    Osteoporosis International, 2015
    Co-Authors: Akinori Sakai, Hitoshi Saito, T Tomomitsu, Hiroshi Tsurukami, Satoshi Ikeda, Fumio Fukuda, Hideki Mizunuma, Tomoyuki Inoue, Toshitaka Nakamura
    Abstract:

    Summary Combined treatment with alendronate and Eldecalcitol was found to be more effective in reducing the bone turnover markers and increasing bone mineral density than alendronate treatment with vitamin D3 and calcium supplementation in the osteoporotic patients.

Toshio Matsumoto - One of the best experts on this subject based on the ideXlab platform.

  • Chapter 93 – Eldecalcitol and Osteoporosis
    Vitamin D, 2020
    Co-Authors: Toshio Matsumoto, Fumiaki Takahashi
    Abstract:

    Abstract Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3] is an analog of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], bearing a hydroxypropyloxy residue at the 2β position. Its chemical structure gives Eldecalcitol unique features of actions with long serum half-life, lower affinity but stable binding to vitamin D receptor, and little metabolism via 24-hydroxylation. Eldecalcitol suppresses bone resorption to a greater extent than alfacalcidol by reducing osteoclast number but has a similar effect on bone formation because of resorption-independent minimodeling, resulting in a greater increase in bone mineral density in ovariectomized rats. In osteoporotic patients, Eldecalcitol shows stronger effects than alfacalcidol in increasing bone mineral density and reducing bone resorption markers. Once-daily 0.75 μg Eldecalcitol reduces the incidence of vertebral fracture compared with 1.0 μg alfacalcidol. In addition, Eldecalcitol strongly reduces wrist fracture incidence. It is not known whether Eldecalcitol has a stronger effect in preventing falls than alfacalcidol.

  • Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)
    Journal of Bone and Mineral Metabolism, 2020
    Co-Authors: Toshio Matsumoto, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Tetsuo Nakano, T Tomomitsu, Akihiro Hirakawa, Satoshi Soen
    Abstract:

    Introduction Eldecalcitol increases bone mineral density (BMD) and reduces vertebral fracture in patients with primary osteoporosis. However, the effect of Eldecalcitol on BMD and fracture in glucocorticoid-induced osteoporosis (GIO) patients is unknown. This study was undertaken to compare the effect of Eldecalcitol on BMD and fracture with that of alfacalcidol in GIO patients. Materials and methods A randomized, open-label, parallel group study was conducted to identify the effectiveness and safety of monotherapy with 0.75 μg Eldecalcitol compared with 1.0 μg alfacalcidol in GIO patients. Results Lumbar spine BMD increased with Eldecalcitol, but decreased with alfacalcidol at 12 and 24 months (between group difference 1.29%, p 

  • Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid induced osteoporosis patients e gloria
    Journal of Bone and Mineral Metabolism, 2020
    Co-Authors: Toshio Matsumoto, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Tetsuo Nakano, T Tomomitsu, Akihiro Hirakawa, Satoshi Soen
    Abstract:

    Eldecalcitol increases bone mineral density (BMD) and reduces vertebral fracture in patients with primary osteoporosis. However, the effect of Eldecalcitol on BMD and fracture in glucocorticoid-induced osteoporosis (GIO) patients is unknown. This study was undertaken to compare the effect of Eldecalcitol on BMD and fracture with that of alfacalcidol in GIO patients. A randomized, open-label, parallel group study was conducted to identify the effectiveness and safety of monotherapy with 0.75 μg Eldecalcitol compared with 1.0 μg alfacalcidol in GIO patients. Lumbar spine BMD increased with Eldecalcitol, but decreased with alfacalcidol at 12 and 24 months (between group difference 1.29%, p   70% of the young adult mean, and with ≤ 3 months of previous glucocorticoid treatment. No significant difference in the incidence of vertebral fracture was found, and the incidence of adverse events was similar between the two groups. Eldecalcitol was more effective than alfacalcidol in maintaining BMD in GIO patients. Because Eldecalcitol was effective in patients with no or short-term previous glucocorticoid treatment, as well as those without prevalent fracture or low BMD, Eldecalcitol can be a good candidate for primary prevention of GIO. UMIN000011700.

  • Eldecalcitol increases bone mineral density in chinese osteoporotic patients without vitamin d or calcium supplementation
    Journal of Bone and Mineral Metabolism, 2019
    Co-Authors: Yan Jiang, Hai Tang, Qun Cheng, Zhenlin Zhang, Wei Yu, Shuli He, Tsuyoshi Kobayashi, Satomi Uehara, Toshio Matsumoto
    Abstract:

    : Eldecalcitol increased bone mineral density (BMD) and prevented vertebral fractures in vitamin D-sufficient osteoporotic subjects. However, the effect of Eldecalcitol on BMD under vitamin D insufficiency is unknown. We examined the effect of Eldecalcitol on BMD compared with alfacalcidol in osteoporotic patients without vitamin D or calcium supplementation. This is a randomized, double-blind, active comparator trial. 265 Chinese osteoporotic patients were randomly assigned to receive 0.75 μg Eldecalcitol or 1.0 μg alfacalcidol for 12 months without vitamin D or calcium supplementation. Baseline calcium intakes were less than 550 mg/day and mean serum 25-hydroxyvitamin D [25(OH)D] was below 43 nmol/L in both groups. Baseline BMD tended to be lower in patients with lower calcium intake and serum 25(OH)D. Lumbar BMD increased by 2.05% higher in Eldecalcitol than alfacalcidol group at 12 months. Total hip and femoral neck BMD also increased by 1.33 and 1.78%, respectively, in the Eldecalcitol than the alfacalcidol group. The effect of Eldecalcitol on BMD was not affected by serum 25(OH)D or calcium intake. The incidence of adverse events was not different between the two groups. Incidence of hypercalcemia in the edecalcitol group was not affected by serum 25(OH)D. In conclusion, baseline BMD tended to be lower in patients with low calcium intake and serum 25(OH)D. Eldecalcitol increased lumbar and hip BMD more than alfacalcidol regardless of serum 25(OH)D or calcium intake without vitamin D or calcium supplementation. These results suggest that Eldecalcitol is effective in increasing the BMD of osteoporotic patients regardless of vitamin D status or calcium intake.Clinical Trial Registration number JAPIC CTI 152904.

  • chapter 93 Eldecalcitol and osteoporosis
    Vitamin D (Fourth Edition)#R##N#Volume 2: Health Disease and Therapeutics, 2018
    Co-Authors: Toshio Matsumoto, Fumiaki Takahashi
    Abstract:

    Abstract Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3] is an analog of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], bearing a hydroxypropyloxy residue at the 2β position. Its chemical structure gives Eldecalcitol unique features of actions with long serum half-life, lower affinity but stable binding to vitamin D receptor, and little metabolism via 24-hydroxylation. Eldecalcitol suppresses bone resorption to a greater extent than alfacalcidol by reducing osteoclast number but has a similar effect on bone formation because of resorption-independent minimodeling, resulting in a greater increase in bone mineral density in ovariectomized rats. In osteoporotic patients, Eldecalcitol shows stronger effects than alfacalcidol in increasing bone mineral density and reducing bone resorption markers. Once-daily 0.75 μg Eldecalcitol reduces the incidence of vertebral fracture compared with 1.0 μg alfacalcidol. In addition, Eldecalcitol strongly reduces wrist fracture incidence. It is not known whether Eldecalcitol has a stronger effect in preventing falls than alfacalcidol.

Sadaoki Sakai - One of the best experts on this subject based on the ideXlab platform.

  • Sequential Treatment with Eldecalcitol After PTH Improves Bone Mechanical Properties of Lumbar Spine and Femur in Aged Ovariectomized Rats
    Calcified Tissue International, 2019
    Co-Authors: Sadaoki Sakai, Hitoshi Saito, Satoshi Takeda, Tomoka Hasegawa, Hiromi Hongo, Tomomaya Yamamoto, Koichi Endo, Kenji Yogo, Norio Amizuka
    Abstract:

    Parathyroid hormone (PTH) analogs have a powerful anabolic effect on bone and are used in the treatment of patients with severe osteoporosis. However, there are limitations to how long they can be safely administered. Withdrawal of PTH results in the cancelation of its effects, necessitating subsequent treatment to maintain the bone quantity and quality. This study assessed the effects of Eldecalcitol (ELD), an active vitamin D3 derivative, after PTH in estrogen-deficient osteoporotic rats. Six-month-old female rats were ovariectomized, and PTH administration was started 7 weeks later. After 4 weeks of PTH treatment, the animals were divided into three groups and either continued to receive PTH (PTH–PTH), or were switched to ELD (PTH–ELD) or vehicle (PTH–Veh) for an additional 4 weeks. In the femur, increased BMD by 4 weeks treatment of PTH was significantly reduced in PTH–Veh but not in PTH–PTH and PTH–ELD. The same tendency was observed in the lumbar vertebrae. MicroCT imaging and histomorphometry analysis revealed that the favorable bone structure changes by PTH administration were also maintained in the femurs and tibias of the PTH–PTH and PTH–ELD groups. Increased bone strength by 4-week treatment of PTH in lumber also maintained in PTH–ELD. Furthermore, minimodeling was observed in the PTH–ELD group. These results demonstrate that treatment with ELD sequentially following PTH prevented the bone quantity and strength reduction that accompanies PTH withdrawal in estrogen-deficient rats.

  • histological effects of the combined administration of Eldecalcitol and a parathyroid hormone in the metaphyseal trabeculae of ovariectomized rats
    Journal of Histochemistry and Cytochemistry, 2019
    Co-Authors: Tomoka Hasegawa, Satoshi Takeda, Paulo Henrique Luiz De Freitas, Minqi Li, Sadaoki Sakai, Hiromi Hongo, Tomomaya Yamamoto, Yukina Miyamoto, Koichi Endo, Norio Amizuka
    Abstract:

    SummaryIntermittent administration of human parathyroid hormone (1-34) (hPTH(1-34)) promotes anabolic action in bone by stimulating bone remodeling, while Eldecalcitol, an analog of active vitamin ...

  • effects of Eldecalcitol on bone and skeletal muscles in glucocorticoid treated rats
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Hayato Kinoshita, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Ayako Shiraishi, Toyohito Segawa, Kentaro Ohuchi, Masashi Fujii, Chie Sato, Yoichi Shimada
    Abstract:

    Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D3 analogue, Eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or Eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg Eldecalcitol); PSL + E group; and control group. PSL, Eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7, MyoD, and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group (p < 0.05) after 4 weeks, but not after 2 weeks. No significant difference in muscle fatigue was seen between groups at 2 or 4 weeks. CSAs of type II muscle fibers were significantly larger in the E group and the PSL + E group than in the PSL group at 4 weeks (p = 0.0093, p = 0.0443, respectively). Eldecalcitol treatment for 4 weeks maintained the same BMD as the PSL + E group. After 2 weeks, but not 4 weeks, Eldecalcitol treatment significantly increased Pax7 and myogenin mRNA expression in gastrocnemius muscle, and PSL also stimulated myogenin expression. Eldecalcitol appears to increase muscle volume and to protect against femur BMD loss in PSL-administered rats, and it may also stimulate myoblast differentiation into early myotubes.

  • Effects of Eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Hayato Kinoshita, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Ayako Shiraishi, Toyohito Segawa, Kentaro Ohuchi, Masashi Fujii, Chie Sato, Yoichi Shimada
    Abstract:

    Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D_3 analogue, Eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or Eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg Eldecalcitol); PSL + E group; and control group. PSL, Eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7 , MyoD , and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group ( p  

  • Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence accelerated sam p6 mice a comparison with alfacalcidol
    The Journal of Steroid Biochemistry and Molecular Biology, 2014
    Co-Authors: Ayako Shiraishi, Hitoshi Saito, Sadaoki Sakai, Fumiaki Takahashi
    Abstract:

    Abstract Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH) 2 D 3 , is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated mouse strain P6 (SAM/P6), which has low bone mass caused by osteoblast dysfunction, to evaluate the effect of ELD on cortical bone in comparison with ALF. Four-month-old SAM/P6 mice were given either ELD (0.025 or 0.05 μg/kg) or ALF (0.2 or 0.4 μg/kg) by oral gavage 5 times/week for 6 weeks. Both ELD and ALF increased serum calcium (Ca) in a dose-dependent manner. Serum Ca levels in the ELD 0.05 μg/kg group were comparable to those of the ALF 0.2 μg/kg group. ELD 0.05 μg/kg significantly improved the bone biomechanical properties of the femur compared with the vehicle control group ( p p p p p This article is part of a Special Issue entitled ‘16th Vitamin D Workshop’.

Yoichi Shimada - One of the best experts on this subject based on the ideXlab platform.

  • effects of Eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant induced arthritis
    Osteoporosis and sarcopenia, 2018
    Co-Authors: Naohisa Miyakoshi, Yuji Kasukawa, Hiroyuki Nagasawa, Hiroyuki Tsuchie, Manabu Akagawa, Itsuki Nagahata, Yusuke Yuasa, Chiaki Sato, Yoichi Shimada
    Abstract:

    Abstract Objectives Rheumatoid arthritis (RA) is characterized by chronic inflammation of the synovium, progressive erosion of the articular cartilage, and joint destruction. RA also causes secondary osteoporosis and muscle wasting. We investigated the effects of ibandronate (IBN), a bisphosphonate; Eldecalcitol (ELD), an active vitamin D3 derivative; and combination treatment with both agents on secondary osteoporosis and muscle wasting using adjuvant-induced arthritis rats. Methods Arthritis was induced in 8-week-old male Lewis rats. Rats were randomized into 4 treatment groups and an untreated normal control group: IBN (subcutaneously, once every 2 weeks, 10 μg/kg), ELD (orally, once daily, 30 ng/kg/day), IBN + ELD, vehicle, and control. Paw thickness measurements were performed for evaluation of arthritis. The femur was scanned using dual-energy X-ray absorptiometry. Cross-sectional areas of left tibialis and anterior muscle fibers and the expression of MuRF1, atrogin-1, MyoD, and myogenin in the gastrocnemius muscle were measured to evaluate muscle wasting. Results IBN and/or ELD increased bone mineral density (BMD) in the femur. In addition, there was an additive effect of combination treatment compared with single treatments for BMD. However, IBN and/or ELD did not inhibit muscle wasting in adjuvant-induced arthritis rats. Conclusions Combination treatment with IBN and ELD may be effective for secondary osteoporosis associated with RA. Other treatments are necessary for muscle wasting associated with RA. Studies in humans are needed to confirm these findings.

  • Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Kimio Saito, Naohisa Miyakoshi, Toshiki Matsunaga, Michio Hongo, Yuji Kasukawa, Yoichi Shimada
    Abstract:

    The antifracture efficacy of vitamin D in osteoporosis is due to its direct action on bones and indirect extraskeletal effects to prevent falls. Eldecalcitol is an analog of active vitamin D_3 that improves bone mineral density and reduces the risk of osteoporotic fractures. However, the effects of Eldecalcitol on muscle strength and static and dynamic postural balance are unclear. In this open-label randomized controlled study, we assessed the effects of Eldecalcitol on muscle strength and static and dynamic postural balance in 50 postmenopausal women (mean age 74 years) with osteoporosis treated with bisphosphonate. Participants were randomly divided into a bisphosphonate group (alendronate at 35 mg/week; n  = 25) or an Eldecalcitol group (Eldecalcitol at 0.75 μg/day and alendronate at 35 mg/week; n  = 25) and were followed up for 6 months. Trunk muscle strength, including back extensor strength and iliopsoas muscle strength, was measured. Static standing balance was evaluated and the one leg standing test was performed to assess static postural balance. Dynamic sitting balance was evaluated and the 10-m walk test, functional reach test, and timed up and go test were performed to assess dynamic postural balance. At 6 months, there were no significant changes in any measure of muscle strength or balance in the bisphosphonate group, whereas Eldecalcitol significantly increased back extensor strength ( p  = 0.012) and iliopsoas muscle strength ( p  = 0.035). Eldecalcitol also significantly improved findings on the timed up and go test ( p  = 0.001) and dynamic sitting balance ( p  = 0.015) at 6 months. These results with Eldecalcitol may have an impact on prevention of falls.

  • effects of Eldecalcitol on bone and skeletal muscles in glucocorticoid treated rats
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Hayato Kinoshita, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Ayako Shiraishi, Toyohito Segawa, Kentaro Ohuchi, Masashi Fujii, Chie Sato, Yoichi Shimada
    Abstract:

    Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D3 analogue, Eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or Eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg Eldecalcitol); PSL + E group; and control group. PSL, Eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7, MyoD, and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group (p < 0.05) after 4 weeks, but not after 2 weeks. No significant difference in muscle fatigue was seen between groups at 2 or 4 weeks. CSAs of type II muscle fibers were significantly larger in the E group and the PSL + E group than in the PSL group at 4 weeks (p = 0.0093, p = 0.0443, respectively). Eldecalcitol treatment for 4 weeks maintained the same BMD as the PSL + E group. After 2 weeks, but not 4 weeks, Eldecalcitol treatment significantly increased Pax7 and myogenin mRNA expression in gastrocnemius muscle, and PSL also stimulated myogenin expression. Eldecalcitol appears to increase muscle volume and to protect against femur BMD loss in PSL-administered rats, and it may also stimulate myoblast differentiation into early myotubes.

  • Effects of Eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Hayato Kinoshita, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Ayako Shiraishi, Toyohito Segawa, Kentaro Ohuchi, Masashi Fujii, Chie Sato, Yoichi Shimada
    Abstract:

    Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D_3 analogue, Eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or Eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg Eldecalcitol); PSL + E group; and control group. PSL, Eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7 , MyoD , and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group ( p  

Ayako Shiraishi - One of the best experts on this subject based on the ideXlab platform.

  • effects of Eldecalcitol on bone and skeletal muscles in glucocorticoid treated rats
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Hayato Kinoshita, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Ayako Shiraishi, Toyohito Segawa, Kentaro Ohuchi, Masashi Fujii, Chie Sato, Yoichi Shimada
    Abstract:

    Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D3 analogue, Eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or Eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg Eldecalcitol); PSL + E group; and control group. PSL, Eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7, MyoD, and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group (p < 0.05) after 4 weeks, but not after 2 weeks. No significant difference in muscle fatigue was seen between groups at 2 or 4 weeks. CSAs of type II muscle fibers were significantly larger in the E group and the PSL + E group than in the PSL group at 4 weeks (p = 0.0093, p = 0.0443, respectively). Eldecalcitol treatment for 4 weeks maintained the same BMD as the PSL + E group. After 2 weeks, but not 4 weeks, Eldecalcitol treatment significantly increased Pax7 and myogenin mRNA expression in gastrocnemius muscle, and PSL also stimulated myogenin expression. Eldecalcitol appears to increase muscle volume and to protect against femur BMD loss in PSL-administered rats, and it may also stimulate myoblast differentiation into early myotubes.

  • Effects of Eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats
    Journal of Bone and Mineral Metabolism, 2016
    Co-Authors: Hayato Kinoshita, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Ayako Shiraishi, Toyohito Segawa, Kentaro Ohuchi, Masashi Fujii, Chie Sato, Yoichi Shimada
    Abstract:

    Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D_3 analogue, Eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or Eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg Eldecalcitol); PSL + E group; and control group. PSL, Eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7 , MyoD , and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group ( p  

  • Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence accelerated sam p6 mice a comparison with alfacalcidol
    The Journal of Steroid Biochemistry and Molecular Biology, 2014
    Co-Authors: Ayako Shiraishi, Hitoshi Saito, Sadaoki Sakai, Fumiaki Takahashi
    Abstract:

    Abstract Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH) 2 D 3 , is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated mouse strain P6 (SAM/P6), which has low bone mass caused by osteoblast dysfunction, to evaluate the effect of ELD on cortical bone in comparison with ALF. Four-month-old SAM/P6 mice were given either ELD (0.025 or 0.05 μg/kg) or ALF (0.2 or 0.4 μg/kg) by oral gavage 5 times/week for 6 weeks. Both ELD and ALF increased serum calcium (Ca) in a dose-dependent manner. Serum Ca levels in the ELD 0.05 μg/kg group were comparable to those of the ALF 0.2 μg/kg group. ELD 0.05 μg/kg significantly improved the bone biomechanical properties of the femur compared with the vehicle control group ( p p p p p This article is part of a Special Issue entitled ‘16th Vitamin D Workshop’.

  • Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.
    The Journal of Steroid Biochemistry and Molecular Biology, 2014
    Co-Authors: Ayako Shiraishi, Hitoshi Saito, Sadaoki Sakai, Fumiaki Takahashi
    Abstract:

    Abstract Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH) 2 D 3 , is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated mouse strain P6 (SAM/P6), which has low bone mass caused by osteoblast dysfunction, to evaluate the effect of ELD on cortical bone in comparison with ALF. Four-month-old SAM/P6 mice were given either ELD (0.025 or 0.05 μg/kg) or ALF (0.2 or 0.4 μg/kg) by oral gavage 5 times/week for 6 weeks. Both ELD and ALF increased serum calcium (Ca) in a dose-dependent manner. Serum Ca levels in the ELD 0.05 μg/kg group were comparable to those of the ALF 0.2 μg/kg group. ELD 0.05 μg/kg significantly improved the bone biomechanical properties of the femur compared with the vehicle control group ( p p p p p This article is part of a Special Issue entitled ‘16th Vitamin D Workshop’.

  • Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.
    The Journal of steroid biochemistry and molecular biology, 2013
    Co-Authors: Ayako Shiraishi, Hitoshi Saito, Sadaoki Sakai, Fumiaki Takahashi
    Abstract:

    Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated mouse strain P6 (SAM/P6), which has low bone mass caused by osteoblast dysfunction, to evaluate the effect of ELD on cortical bone in comparison with ALF. Four-month-old SAM/P6 mice were given either ELD (0.025 or 0.05μg/kg) or ALF (0.2 or 0.4μg/kg) by oral gavage 5 times/week for 6 weeks. Both ELD and ALF increased serum calcium (Ca) in a dose-dependent manner. Serum Ca levels in the ELD 0.05μg/kg group were comparable to those of the ALF 0.2μg/kg group. ELD 0.05μg/kg significantly improved the bone biomechanical properties of the femur compared with the vehicle control group (p